A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
A PHASE 3 STUDY IN INDIA TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前:Pfizer CT.gov Call Center
- 電話番号:1-800-718-1021
- メール:ClinicalTrials.gov_Inquiries@pfizer.com
研究場所
-
-
Andhra Pradesh
-
Visakhapatnam、Andhra Pradesh、インド、530002
- 募集
- King George Hospital
-
-
Karnataka
-
Bangalore、Karnataka、インド、560060
- 募集
- BGS Global Institute of Medical Sciences (BGSGIMS)
-
Bangalore、Karnataka、インド、560085
- 募集
- Radhakrishna Multispeciality Hospital and IVF Center
-
Belagavi、Karnataka、インド、590001
- 募集
- Belagavi Institute of Medical Sciences - Belagavi
-
-
Maharashtra
-
Nashik、Maharashtra、インド、422003
- 募集
- Suyog Hospital
-
Pune、Maharashtra、インド、411043
- 募集
- Bharati Vidyapeeth {Deemed to be University) Medical College Hospital & Research Centre
-
-
National Capital Territory of Delhi
-
Dwarka、National Capital Territory of Delhi、インド、110075
- 募集
- Aakash Healthcare Private Limited
-
New Delhi、National Capital Territory of Delhi、インド、110060
- 募集
- Sir Ganga Ram Hospital
-
New Delhi、National Capital Territory of Delhi、インド、110029
- 募集
- All India Institute Of Medical Sciences
-
-
Rajasthan
-
Jaipur、Rajasthan、インド、302039
- 募集
- Maharaja Agrasen Superspeciality Hospital
-
-
Tamil Nadu
-
Chengalpattu、Tamil Nadu、インド、603203
- 募集
- SRM Medical College Hospital and Research Centre - Kattankulathur
-
Kelambākkam、Tamil Nadu、インド、603103
- 募集
- Chettinad Hospital and Research Institute
-
-
West Bengal
-
Kolkata、West Bengal、インド、700020
- 募集
- Institute of Post Graduate Medical Education & Research, SSKM Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Participants ≥18 years of age at Visit 1.
- Participants who are ambulatory and live independently in the community.
- Participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
- Applicable to participants 18 through 59 years of age: Participants who are healthy or have stable preexisting diseases. These participants are considered at high risk of RSV disease by having at least 1 reportable stable chronic medical condition(s) that belongs to 1 or more of the following:
- Chronic heart disease (ie, coronary artery disease, heart failure, or congenital heart disease)
- Chronic lung disease (ie, COPD, emphysema, asthma, interstitial lung disease, or cystic fibrosis)
- Nongestational diabetes mellitus type 1 or type 2
- Severe obesity (body mass index [BMI] ≥40 kg/m2)
- Chronic liver disease (ie, cirrhosis)
- Chronic kidney disease (not including end-stage renal disease with or without dialysis)
- Chronic neurological disease that causes impaired airway clearance or respiratory muscle weakness (ie, poststroke dysphagia, amyotrophic lateral sclerosis, or muscular dystrophy)
- Chronic hematologic disease (ie, sickle cell disease or thalassemia)
Note: A chronic medical condition for this study is defined as:
- Duration ≥6 months.
- Requires regular medical follow-up or ongoing prescribed medication or hospitalization in the previous year.
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in the protocol.
Key Exclusion Criteria:
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
- Prior history of any subtype of Guillain-Barré syndrome of any etiology.
- Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
- Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo
Placebo |
Placebo |
|
実験的:RSVpreF
RSVpreF Vaccine |
RSVpreF Vaccine |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titers (GMT)
時間枠:Before vaccination, 1 month after vaccination
|
Before vaccination, 1 month after vaccination
|
|
|
NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)
時間枠:Before vaccination, 1 month after vaccination
|
Before vaccination, 1 month after vaccination
|
|
|
NTs for RSV A and RSV B expressed as seroresponse rate
時間枠:1 month after vaccination
|
1 month after vaccination
|
|
|
Proportion of participants reporting local reactions within 7 days following investigational product administration
時間枠:Within 7 days
|
Describe local reactions following investigational product administration |
Within 7 days
|
|
Percentage of participants reporting systemic events within 7 days following investigational product administration
時間枠:Within 7 days
|
Describe systemic events following investigational product administration |
Within 7 days
|
|
Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration
時間枠:1 month after vaccination
|
Describe AEs occurring through 1 month following administration of investigational product |
1 month after vaccination
|
|
Percentage of participants reporting serious adverse events (SAEs) throughout the study
時間枠:3 months after vaccination
|
Describe SAEs through 3 months following administration of investigational product |
3 months after vaccination
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Pfizer CT.gov Call Center、Pfizer
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- C3671040
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。